Tjokrowidjaja A, Lee CK, Friedlander M, Gebski V, et al. Concordance between CA-125 and RECIST progression in patients with germline
BRCA-mutated platinum-sensitive relapsed ovarian cancer treated in the SOLO2
trial with olaparib as maintenance therapy after response to chemotherapy. Eur J Cancer 2020;139:59-67.
PMID: 32977221